Can neurofilament lightchain as endpoint in Phase 2 derisk clinical disability worsening in Phase 3 in multiple sclerosis?

Collignon, O

Collignon, O (通讯作者)，GSK, 980 Great West Rd, London TW8 9GS, England.

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023; 80 ():

Abstract

Background: Neurofilament lightchain has been proposed as a Phase 2 endpoint in clinical trials for multiple sclerosis. We evaluated via simulations t......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索